vs

Side-by-side financial comparison of Taysha Gene Therapies, Inc. (TSHA) and VerifyMe, Inc. (VRME). Click either name above to swap in a different company.

Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $5.0M, roughly 1.1× VerifyMe, Inc.). VerifyMe, Inc. runs the higher net margin — -66.7% vs -507.8%, a 441.1% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -7.4%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -5.2%).

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.

VerifyMe, Inc. is a technology provider specializing in identity verification, anti-counterfeiting, and brand protection solutions. Its offerings include secure authentication tools, supply chain traceability systems, and customer engagement platforms, serving consumer goods, pharmaceutical, and retail sectors across North America and select global markets.

TSHA vs VRME — Head-to-Head

Bigger by revenue
TSHA
TSHA
1.1× larger
TSHA
$5.5M
$5.0M
VRME
Growing faster (revenue YoY)
TSHA
TSHA
+178.7% gap
TSHA
171.3%
-7.4%
VRME
Higher net margin
VRME
VRME
441.1% more per $
VRME
-66.7%
-507.8%
TSHA
Faster 2-yr revenue CAGR
TSHA
TSHA
Annualised
TSHA
26.8%
-5.2%
VRME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
TSHA
TSHA
VRME
VRME
Revenue
$5.5M
$5.0M
Net Profit
$-27.9M
$-3.4M
Gross Margin
41.2%
Operating Margin
-516.0%
-68.2%
Net Margin
-507.8%
-66.7%
Revenue YoY
171.3%
-7.4%
Net Profit YoY
-48.3%
-38.4%
EPS (diluted)
$-0.08
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TSHA
TSHA
VRME
VRME
Q4 25
$5.5M
Q3 25
$0
$5.0M
Q2 25
$2.0M
$4.5M
Q1 25
$2.3M
$4.5M
Q4 24
$2.0M
Q3 24
$1.8M
$5.4M
Q2 24
$1.1M
$5.4M
Q1 24
$3.4M
$5.8M
Net Profit
TSHA
TSHA
VRME
VRME
Q4 25
$-27.9M
Q3 25
$-32.7M
$-3.4M
Q2 25
$-26.9M
$-291.0K
Q1 25
$-21.5M
$-571.0K
Q4 24
$-18.8M
Q3 24
$-25.5M
$-2.4M
Q2 24
$-20.9M
$-346.0K
Q1 24
$-24.1M
$-553.0K
Gross Margin
TSHA
TSHA
VRME
VRME
Q4 25
Q3 25
41.2%
Q2 25
35.2%
Q1 25
33.4%
Q4 24
Q3 24
34.9%
Q2 24
39.1%
Q1 24
39.2%
Operating Margin
TSHA
TSHA
VRME
VRME
Q4 25
-516.0%
Q3 25
-68.2%
Q2 25
-1347.1%
-7.1%
Q1 25
-930.5%
-13.3%
Q4 24
-985.8%
Q3 24
-1448.4%
-52.8%
Q2 24
-1915.4%
-10.0%
Q1 24
-713.3%
-11.2%
Net Margin
TSHA
TSHA
VRME
VRME
Q4 25
-507.8%
Q3 25
-66.7%
Q2 25
-1353.6%
-6.4%
Q1 25
-935.2%
-12.8%
Q4 24
-929.0%
Q3 24
-1427.5%
-44.6%
Q2 24
-1882.0%
-6.5%
Q1 24
-705.4%
-9.6%
EPS (diluted)
TSHA
TSHA
VRME
VRME
Q4 25
$-0.08
Q3 25
$-0.09
$-0.26
Q2 25
$-0.09
$-0.02
Q1 25
$-0.08
$-0.05
Q4 24
$-0.07
Q3 24
$-0.10
$-0.23
Q2 24
$-0.09
$-0.03
Q1 24
$-0.10
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TSHA
TSHA
VRME
VRME
Cash + ST InvestmentsLiquidity on hand
$319.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$246.9M
$11.1M
Total Assets
$343.3M
$13.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TSHA
TSHA
VRME
VRME
Q4 25
$319.8M
Q3 25
$297.3M
Q2 25
$312.8M
Q1 25
$116.6M
Q4 24
$139.0M
Q3 24
$157.7M
$2.6M
Q2 24
$172.7M
$2.9M
Q1 24
$124.0M
$2.8M
Total Debt
TSHA
TSHA
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$500.0K
Q2 24
$600.0K
Q1 24
$800.0K
Stockholders' Equity
TSHA
TSHA
VRME
VRME
Q4 25
$246.9M
Q3 25
$219.0M
$11.1M
Q2 25
$248.7M
$14.4M
Q1 25
$55.1M
$14.6M
Q4 24
$71.5M
Q3 24
$88.8M
$10.3M
Q2 24
$108.9M
$12.3M
Q1 24
$53.8M
$12.4M
Total Assets
TSHA
TSHA
VRME
VRME
Q4 25
$343.3M
Q3 25
$316.6M
$13.3M
Q2 25
$333.3M
$17.2M
Q1 25
$138.4M
$17.1M
Q4 24
$160.4M
Q3 24
$180.2M
$14.8M
Q2 24
$200.4M
$17.5M
Q1 24
$153.0M
$17.9M
Debt / Equity
TSHA
TSHA
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.05×
Q2 24
0.05×
Q1 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TSHA
TSHA
VRME
VRME
Operating Cash FlowLast quarter
$-26.7M
$243.0K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TSHA
TSHA
VRME
VRME
Q4 25
$-26.7M
Q3 25
$-24.2M
$243.0K
Q2 25
$-20.2M
$710.0K
Q1 25
$-22.0M
$-404.0K
Q4 24
$-18.3M
Q3 24
$-21.6M
$-10.0K
Q2 24
$-21.5M
$372.0K
Q1 24
$-19.8M
$-60.0K
Free Cash Flow
TSHA
TSHA
VRME
VRME
Q4 25
Q3 25
$-24.3M
Q2 25
Q1 25
Q4 24
$-18.3M
Q3 24
$-21.6M
$-12.0K
Q2 24
$-21.7M
$369.0K
Q1 24
$-19.9M
$-62.0K
FCF Margin
TSHA
TSHA
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-905.5%
Q3 24
-1210.9%
-0.2%
Q2 24
-1951.9%
6.9%
Q1 24
-584.5%
-1.1%
Capex Intensity
TSHA
TSHA
VRME
VRME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.1%
Q3 24
2.0%
0.0%
Q2 24
18.1%
0.1%
Q1 24
4.1%
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TSHA
TSHA

Segment breakdown not available.

VRME
VRME

Proactive Services$4.2M83%
Other$869.0K17%

Related Comparisons